Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17911781 | 1.00 | ALDH1A1 (0.58) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL10868499 | 0.86 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL17919043 | 0.86 | ALDH1A1 (0.43) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL7155546 | 0.79 | ALDH1A1 (0.65) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL7155543 | 0.79 | ALDH1A1 (0.65) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| Bromide SCHEMBL28686876 | 0.78 | ALDH1A1 (0.64) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL17956609 | 0.78 | LMNA (0.56) | ALDH1A1THRBKMT2A | |
| SCHEMBL10868507 | 0.77 | ALDH1A1 (0.57) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL20281076 | 0.77 | ALDH1A1 (0.79) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL26792172 | 0.77 | ALDH1A1 (0.79) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787476-B2 | Glycoamino acid and use thereof | AJINOMOTO CO., INC. (JP) | 2020-09-29 | — | — | US | disclosed |
| US-10787476-B2 | Glycoamino acid and use thereof | AJINOMOTO CO., INC. (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3050893-B1 | GLYCOAMINO ACID AND USE THEREOF | AJINOMOTO KK (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3050893-A1 | GLYCOAMINO ACID AND USE THEREOF | Ajinomoto Co., Inc. (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20160200755-A1 | GLYCOAMINO ACID AND USE THEREOF | AJINOMOTO CO., INC. (JP) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200755-A1 | GLYCOAMINO ACID AND USE THEREOF | GYPA, NGLY1, SLC6A15 | ALDH1A1 1637/4885THRB 2264/4885MAPK1 1237/4885 |
| US-10787476-B2 | Glycoamino acid and use thereof | GYPA, NGLY1, SLC6A15 | ALDH1A1 1637/4885THRB 2264/4885MAPK1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.